Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cefuroxime, levofloxacin, esomeprazole, and bismuth as first-line therapy for eradicating Helicobacter pylori in patients allergic to penicillin

Published:2019-07-25 Issue:1 Volume:19 Page:
ISSN:1471-230X
Container-title:BMC Gastroenterology
language:en
Short-container-title:BMC Gastroenterol

Author:

Song Zhiqiang,Fu Wei,Zhou Liya

Funder

the National Science & Technology Pillar Program of the twelfth Five-Year Plan in China

the National Natural Science Foundation of China

the clinical key projects of Peking University Third Hospital

the key laboratory for Helicobacter pylori infection and upper gastrointestinal diseases in Beijing

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12876-019-1056-3.pdf

Reference37 articles.

1. Malfertheiner P, Megraud F, O'Morain CA, Gisbert JP, Kuipers EJ, Axon AT, et al. Management of Helicobacter pylori infection-the Maastricht V/Florence consensus report. Gut. 2017;66(1):6–30.

2. Song Z, Zhang J, He L, Chen M, Hou X, Li Z, et al. Prospective multi-region study on primary antibiotic resistance of helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis. 2014;46(12):1077–81.

3. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010;59(8):1143–53.

4. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut. 2013;62(1):34–42.

5. Graham DY. Hp-normogram (normo-graham) for assessing the outcome of H. pylori therapy: effect of resistance, duration, and CYP2C19 genotype. Helicobacter. 2016;21(2):85–90.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Application of cefuroxime in the eradication therapy of Helicobacter pylori infection: A review article;Helicobacter;2024-03

2. A retrospective pharmacovigilance study of post-marketing safety concerns with cefuroxime;Therapeutic Advances in Drug Safety;2024-01

3. Newer, Older, and Alternative Agents for the Eradication of Helicobacter pylori Infection: A Narrative Review;Antibiotics;2023-05-23

4. Overview of Helicobacter pylori Infection, Prevalence, Risk Factors, and Its Prevention;Advanced Gut & Microbiome Research;2023-05-10

5. Treatment of Helicobacter pylori Infection in Patients with Penicillin Allergy;Antibiotics;2023-04-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3